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Abstract 
CLINICAL AND DEMOGRAPHIC CORRELATES OF DEPRESSSION IN STABLE HEART 
FAILURE 
In this secondary analysis of cross sectional data collected from 173 patients with chronic HF the 
demographic, clinical, and sleep related factors present in patients with stable HF and major 
depressive disorder (MDD) were explored. Participants were recruited from 5 structured HF 
disease management programs in the Northeastern US. Measures include the Centers for 
Epidemiological Studies Depression Scale (CESD), the Charlson Comorbidity Index (CCI), and 
a sleep diary. Results indicate significant between group differences between patients with MDD 
and without MDD in age, gender, NYHA, diabetes, chronic fatigue, asthma, past psychiatric 
history, antidepressant use, anxiolytic use, insomnia, and taking sleeping pills. A logistic 
regression incorporating age, gender, NYHA class, asthma, diabetes, and insomnia predicted 
84.6% of patients with and without MDD, with insomnia remaining significant at a p = 0.002. 
Major Depressive Disorder (MDD) is a common and under-diagnosed co-morbidity in stable 
heart failure (HF), associated with worse outcomes and lower quality of life. Further 
identification of the factors associated with MDD in patients with stable HF may help to improve 
rates of diagnosis and treatment. Self reported insomnia was present in the majority of depressed 
patients. Other characteristics of depressed patients in the sample include younger age, female 
gender, NYHA class III/IV, and co-morbid asthma and diabetes. 
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Introduction 
Depression is common among the 5.8 million people who live with HF in the United States and 
is associated with increased morbidity, mortality, healthcare costs, and decreased quality of life 
(Hallas, Wray, Andreou, & Banner, 2011; Smith, 2010). Recent reviews suggest that rates of 
depression among patients with HF range from 13-77%, although the wide range is likely due to 
variability in the methods used to measure depression, definitions of depression as depressive 
symptoms versus clinical depression, and whether or not patients were hospitalized at the time of 
diagnosis (Delville & McDougall, 2008; Redeker, 2006). This compares with a prevalence of 
Major Depressive Disorder (MDD) in 10%-25% of women and 5-12% of men in the general 
population (APA, 2000). Depression is associated with poorer function, decreased quality of life, 
increase in symptoms, increased mortality, and increased hospitalizations in patients with HF, 
independent of severity of HF (Friedmann, et al., 2006; Hallas, et al, 2011; Lea, 2009; Sherwood, 
et al., 2011; Ramasay, et al., 2006; Sullivan, Levy, Russo, & Spertus, 2004).  Depression may 
also be a risk factor for developing HF, particularly in high risk cardiac patients (Joynt, Whellan, 
& O’Connor, 2004).  
Patients with MDD are more likely to be classified as NYHA class III & IV, even when 
these classifications cannot be explained by CV risk factors or lab work (Skotzko, 2009). The 
overlap of symptoms and physiology between MDD and HF can lead to exacerbation of 
symptoms, posing difficulties for both diagnosis and treatment. MDD also complicates 
management of HF as it is linked to decreased compliance with HF treatment and low levels of 
social support, both of which are associated with poor outcomes in HF, particularly in older 
adults and patients with increased daytime sleepiness (Joynt et al, 2004; Luttik, Jaarsma, Moser, 
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Sanderman, & van Veldhuisen, 2005; Maixner, Struble, Blazek, Kales, 2011; Riegel, et al., 
2011).  
Although experts recommend screening all HF patients for MDD, especially those with 
New York Heart Association Class III and IV HF (Skotzko, 2009; Lea, 2009; US Preventative 
Task Force, 2009), depression remains under-diagnosed and under-treated in these patients. The 
diagnosis of MDD is missed in approximately 16% of patients with HF in the primary care 
setting (Delville and McDougall, 2008), and cardiologists inquire about depressive symptoms in 
fewer than half of their patients (Feinstein, Blumenfield, Orlowski, Frishman, & Ovanssian, 
2006).  Under-diagnosis of MDD may be due to the shared pathophysiology of HF and MDD, 
including increased catecholamine release, arrhythmias, elaboration of pro-inflammatory 
cytokines and platelet activation (Joynt, Whellan, & O’Connor, 2004; Kupper, Widdershoven, & 
Pedersen, 2011; Lea, 2009) that leads to an overlap in somatic symptoms, such as weight loss, 
pain, distress, dyspnea, fatigue/anergy, disturbed sleep, cachexia, memory problems, and 
functional decline (Skotzko, 2009). The stigma associated with mental illness may also be a 
barrier to patient reports and provider questions about depression. 
Effective diagnosis of MDD is important because the use of antidepressants as part of 
pharmacologic treatment for depression may prevent cardiac deaths (Feinstein, et al; 2006). 
Serotonin reuptake inhibitors (SSRIs) are the most commonly prescribed antidepressants among 
HF patients and can alleviate symptoms of both MDD and dyspnea, common in HF (Feinstein, et 
al, 2006; Ramasamy, et al, 2006). Sertraline specifically improved quality of life in patients with 
HF (Ramasamy et al, 2006). Unfortunately research on treatment options is limited, and some 
evidence suggests that use of anti-depressants may be associated with adverse effects in HF 
patients (Skotzko, 2009). 
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The information on demographic characteristics associated with MDD in stable HF 
patients is limited because many HF studies lack representation of women, young and middle-
aged adults, and minority group members (Bekelman, et al, 2007; Gottlieb, et al, 2004). 
Depression may be more common in women than men, reflecting the trend in the general 
population (Gottlieb, et al, 2004; Lea, 2009; Smith, 2010). Younger age (under 60) and living 
alone are associated with depression in HF patients (Gottlieb, et al, 2004; Smith, 2010). 
However, additional literature reflects no difference in rates of depression along race, gender, or 
age in a study with primarily younger, Caucasian, heart transplant patients with HF (Sullivan, 
Levy, Russo, & Spertus, 2004). 
Self report of depression is associated with in an increase in the number of co-occurring 
disorders in HF patients (Hayashino, et al, 2010). There is limited research on which diagnoses 
are associated with MDD in stable HF patients, with the current literature focusing on 
psychosocial factors and quality of life. Identifying readily available clinical information, such as 
co-morbid conditions and symptoms, may assist providers in identifying patients most at risk for 
having MDD and requiring focused screening and treatment. 
Disturbances in sleep are widespread and highly incapacitating in MDD (Sbarra and 
Allen, 2009). Likewise, sleep disturbance symptoms, such as insomnia, are important to the 
diagnosis of depression in patients with stable HF (Redeker, 2006).  However, the types of sleep 
symptoms in patients with co-morbid MDD and HF remains poorly understood (Norra, et al, 
2011; Wang, et al., 2009).  
The purpose of this study is to describe the demographic and clinical characteristics and 
symptoms of sleep disturbance associated with MDD in patients with stable HF. The following 
  4     4 
research questions were addressed: 1) What is the proportion of stable HF patients who have 
MDD? 2)What is the proportion of patients with MDD who receive antidepressant medication? 
3) What clinical (HF status, number or type of co-morbid conditions) and demographic (age, 
gender, race) characteristics are associated with MDD in stable HF? 4) What characteristics of 
sleep are associated with MDD in stable HF? 
Methods 
The study employed a cross-sectional observational design and consists of secondary analysis of 
data obtained in a project designed to evaluate the contributions of sleep characteristics to 
daytime symptoms and functional performance in patients recruited from five HF disease 
management programs in the Northeastern U.S.  Details of the overall study have previously 
been reported, (Redeker, Jeon, et al., 2010a; Redeker, et al., 2010b), and are summarized here as 
relevant to the current analysis. The study was approved by the institutional review board, and all 
participants provided written informed consent.  
Sample 
The sample included 173 participants who had stable chronic heart failure (mean age =60.3± 
16.8 years; n=60 [35%] female, n=50 [29%] African American; left ventricular ejection fraction 
mean =32±14.6) (Redeker, et al, 2010a). Participants with stable HF were recruited through 
referrals from providers at five HF disease management programs in the Northeastern U.S. 
Eligibility criteria included the following: age >  18 years of age; stable HF (defined as no 
hospital admissions within the previous month or adjustment of vaso-active medications within 
the past 2 weeks); cognitively intact (assessed by clinical judgment). Subjects who were 
pregnant, unstable medically or psychiatrically, or had ongoing alcohol or drug abuse were 
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excluded. Subjects with a history of Parkinson’s disease, obstructive valvular, hypertrophic, or 
surgically correctable valvular disease, renal failure, previously identified sleep disorders, and 
hemiplegia affecting the non-dominant arm (confounding factor for actigraph monitoring) were 
also excluded (Redeker, et al, 2010a). 
Variables and Instruments 
The Center for Epidemiological Studies Depression Scale (CESD) was used to measure 
depressive symptoms. The CESD is a 20-item self report questionnaire. Participants respond to 
each item according to their perceptions over the past week using a four point scale ranging from 
a score of zero for rare (or none of the time) to three points for most (or all of time) (Mulhauser, 
2011). Although a cut-off score of ≥16 indicates a likely diagnosis of MDD in the general 
population (Bardwell, Ancoli-Israel, & Dimsdale, 2006), the presence of somatic symptoms in 
HF suggests that a higher cut-off score would be more specific in cardiac patients (Contrada, 
Boulifard, Idler, Krause, Labouvie, 2006). Therefore, we used a score of ≥ 28 as an indicator of 
MDD (Zich, Attkisson, & Greenfield, 1990). The CESD has a high internal consistency of 0.87 
and sufficient test-retest reliability and sensitivity/specificity (Redeker, et al, 2010a). 
The Charlson Comorbidity Index (CCI) was used as a measure of comorbid conditions. 
The CCI was originally developed for use in longitudinal studies to predict mortality based on 
certain clinical conditions (Charlson, Pompei, Ales, & MacKenzie, 1987). Scores are weighted 
based on severity of illness, and include conditions such as cardiac disease, diabetes, and cancer. 
Demographic data, including age, gender, race, and living alone were obtained through 
participant self-report and interview. Information on comorbid health problems and medications 
was obtained through participant self-report and chart review. Information on sleep symptoms 
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was obtained through self-report. Participants completed a sleep diary for three nights, reporting 
specifics such as sleep latency, number of awakenings, and time of arousal. Sleep diaries are a 
valid and reliable measure of insomnia commonly used in research (Epsie, 1991; Epsie, Inglis, 
Tessier, & Harvey, 2001).  
Procedures 
A research assistant (RA) recruited participants at participating sites during a routine visit to their 
HF program. The assistant explained the study, obtained informed consent, and reviewed 
medical records. Following the initial contact participants completed a packet of questionnaires 
addressing symptoms, depression and quality of life. Only the data on demographics, the CESD, 
the CCI, sleep symptoms, and co-occurring diagnoses are reported here. For the larger study, 
participants also completed one night of polysomnography in their homes and 3 days of wrist 
actigraphy. Upon completion of data collection each participant received $50. (Redeker, et al, 
2010a; Redeker, et al, 2010b) 
Data Analysis   
All data were entered into a database. Full details of this approach have previously been 
described (Redeker, et al, 2010a).  SPSS version 18 was used to compute descriptive statistics 
and to compare the categorical and continuous variables (chi-square, dependent groups t-test) on 
MDD. Covariance among clinical, demographic, and sleep variables was conducted using a 
logistic regression. Clinical and demographic variables included in the regression analysis were 
selected based on their significant bivariate associations with MDD. 
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Results 
Demographic 
Of the 324 patients initially approached, 41 were ineligible, 233 consented, and complete data 
were obtained for 173 participants. The overall sample included 60 females (34.7%) and 61 
minority participants (35.7%). Full details of racial breakdown of participants in the minority 
group were previously reported, and are combined here for ease. The average left ventricular 
ejection fraction is 32.6, NYHA class is 2.5, body mass index 30.7. (Redeker, et al, 2010a)  
 The overall group CESD score was (M = 16.98 + 11.01, range of 0-54). Table 1 lists the 
demographic and clinical characteristics of participants with and without MDD, based on a 
cutoff score of ≥ 28.  
Younger and female participants were significantly more likely to have MDD. There 
were no statistically significant differences in depression based on race or living alone. 
Clinical 
There were statistically significant differences between participants with and without MDD on 
NYHA class, with 59.4% of those with MDD having NYHA class III or IV, but there were no 
statistically significant differences in LVEF. There were no statistically significant differences 
between those with and without MDD on the Charlson Comorbidity Index, but diabetes (MDD 
46.9%, no MDD 24.8%), rheumatoid Arthritis (MDD 21.9%, no MDD 9.3%, p = 0.051), chronic 
fatigue (MDD 18.8%, no MDD 5.7%), asthma (MDD 25%, no MDD 10%), and a past history of 
psychiatric disorders (MDD 47%, no MDD 3.6%) were significantly more common in patients 
with MDD. There were no statistically significant differences between groups with and without 
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MDD on the proportion of patients who had thyroid disease, anemia, osteoarthritis, cancer, 
COPD, GI disorders, or urinary tract disorders. 
Patients with MDD were significantly more likely to be on antidepressants (MDD 33.3%, 
no MDD 10.7%), anxiolytics (MDD 33.3%, no MDD 4.3%), sedative hypnotics (MDD 13.3%, 
no MDD 4.3%), and insulin. The most common class of antidepressants was SSRIs (58.7% 
total). Benzodiazepines were prescribed 81.3% of the time, and Ambien was prescribed 85.7% of 
the time as a sedative hypnotic.  
Sleep Symptoms 
There were statistically significant differences between groups with and without MDD on  sleep 
symptoms , including trouble falling asleep (MDD 64.5%, no MDD 44%), difficulty resuming 
sleep (MDD 58.1%, no MDD 34.8%), waking too early (MDD 58.1%, 29.8%), not feeling rested 
during the day (MDD 80.6%, no MDD 44.7%), feeling overly sleepy during the day (MDD 
67.7%, no MDD 37.6%), and not getting enough sleep (MDD 67.7%, no MDD 42.6%).  
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Table 1  
Comparison of participants with and without clinical depression (MDD) based on score of ≥28 indicating 
MDD on demographic and clinical variables 
 
No MDD  
(N=141 /81.5%) 
MDD 
(N=32/18.5%)  
 
M (SD)/N (%) M (SD)/N (%) 
Demographic Variables 
  Age (mean in years) 61.44 (16.38) 55.53(23.84 
Gender* 
  Male 98(69.5%) 15(45.9%) 
Female 43 (30.5%) 17(53.1%) 
Race 
  White 91 (65.0%) 19 (61.3%) 
Minority 49 (35.0%) 12 (38.7%) 
Living Alone 26 (18.4%) 7 (21.9%) 
Clinical Variables 
  Left ventricular ejection fraction (5) 
  NYHA classification*:  
  Class I, II 87 (61.7%) 13 (40.6%) 
Class III, IV 54 (38.3%) 19 (59.4%) 
Body Mass Index (mean) 30.5 (7.91) 31.7 (8.66) 
Charlson Comorbidy Index (mean) 2.4 (1.51) 2.65 (1.60) 
Diabetes* 35 (24.8%) 15 (46.9%) 
Thyroid Disease 22 (15.8%) 5 (15.6%) 
Anemia 26 (18.6%) 9 (28.1%) 
Rheumatoid Arthritis 13 (9.3%) 7 (21.9%) 
Osteoarthritis 21 (15.0%) 7 (21.9%) 
Cancer 18 (12.9%) 3 (9.4%) 
Chronic Fatigue* 8 (5.7%) 6 (18.8%) 
Asthma* 14 (10.0%) 8 (25.0%) 
COPD 14 (10.0%) 6 (19.4%) 
GI 32 (23.2%) 11 (35.5%) 
Renal 23 (16.4%) 4 (12.5%) 
Psychiatric*** 22(15.9%) 15(46.9%) 
Antidepressant Use*** 15(10.7%) 10(33.3%) 
Sleep Variables 
  Difficulty Initiating and Maintaining sleep*** 60 (43.2%) 26 (83.9%) 
Trouble falling asleep* 62 (44.0%) 20 (64.5%) 
Difficulty Resuming Sleep* 49 (34.8%) 18 (58.1%) 
Waking too early** 42 (29.8%) 18 (58.1%) 
Unrested during day** 63 (44.7%) 25 (80.6%) 
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Overly sleepy** 53 (37.6%) 21 (67.7%) 
Not enough sleep* 60 (42.6%) 21 (67.7%) 
Taking sleeping pills** 13 (9.2%) 10 (32.3%) 
Comparisons for categorical variables used chi-square; comparisons for continuous variables used 
dependent group t-tests.***P < 0.001, **P < 0.01, * P < 0.05 
 
Logistic Regression 
A logistic regression using age (<61), gender (female), NYHA class (III/IV), asthma, diabetes, 
and insomnia, was run with 84.6% prediction for patients with and without MDD. Using this 
model we were able to correctly identify 38.7% of depressed patients, and 95% of non-depressed 
participants. When all six variables were included, age, gender, diabetes, and insomnia remained 
significant (p ≤ 0.05). Insomnia remained the most significant, with a p = 0.002. There was no 
statistically significant finding for NYHA or asthma in the multivariate model. Younger patients 
and patients with diabetes had almost three times the odds of having MDD, women and patients 
with NYHA class III/IV 2.5 times the odds, and patients with asthma had 1.7 times the odds. 
Insomnia increased the odds of MDD 5.5 fold.  
Table 2 
 Logistic Regression of the Associations Among Clinical and  
Demographic Characteristics, Insomnia Symptoms and MDD  
  
OR CI (95) P-value 
Variables 
    Age 
 
2.91 1.14-1.46 0.026 
Gender 
 
2.53 1.00-6.38 0.049 
NYHA 
 
2.48 .99-6.23 0.053 
Diabetes 
 
2.89 1.12-7.46 0.028 
Asthma 
 
1.69 .52-5.53 0.379 
Insomnia 
 
5.42 1.88-15.61 0.002 
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Discussion 
The rates of MDD in this sample (19%) were lower than reported symptoms of 
depression, but were consistent with reports of clinically significant depression in this population 
(Lea, 2009). While symptoms of depression are more common and problematic in patients with 
stable HF, the distinction of patients with clinical depression is important. Patients meeting DSM 
–IV criteria for MDD may be at more risk for complications with their HF and would benefit 
from treatment for their MDD. Our study extends previous work by including a larger proportion 
of women and minority patients, and includes participants who were selected because they had 
stable HF rather than hospitalized patients with acute HF who are often the focus of the literature 
(Norra, et al, 2011). Hospitalized patients are likely to have higher levels of MDD and insomnia 
due to the acuity of their illness and their environment, and may require different evaluation and 
management of symptoms than stable outpatients. 
Unlike many past studies that included few women and either did not report the 
proportion of minority patients or included few minorities, the current study was more 
representative of the general population of HF patients. Therefore the results may be more 
generalizable to typical practice settings. Given that we found no significant differences in rates 
of MDD in minority patients, in contrast to previous literature (Sullivan, et al., 2004), further 
research is needed on the relationship between MDD and race. 
The higher rate of MDD in younger and female patients is consistent with the literature 
(Lea, 2009). This is reflective of higher rates of MDD in females in the general population, 
though it is unclear whether MDD is more common in females or if men are less likely to report 
mood symptoms.  The higher rates of MDD in younger HF patients may be associated with the 
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difficulty of living with a disabling illness at a younger age. We found no significant association 
between living alone and MDD, which had previously been reported as an independent predictor 
for the development of symptoms of depression (Lea, 2009).  
The clinical characteristics significantly related to MDD in this sample were NYHA class 
III/IV, insomnia, diabetes, rheumatoid arthritis, chronic fatigue, asthma, and past psychiatric 
history. Interestingly the number of comorbid conditions was not significantly related to MDD. 
Nearly half (47%) of patients with MDD had a psychiatric history, though only 33% of patients 
with MDD were prescribed antidepressants. This is significant in that more than half of patients 
with MDD do not have a previous history of psychiatric illness, and many patients in treatment 
still have symptoms significant enough to meet criteria for MDD. While we did not specify 
diagnoses for psychiatric history, our results indicate that a large number of patients with MDD 
were under treated. Almost half of the patients in this sample with diabetes scored as clinically 
depressed, indicating that rates of MDD are significantly higher among patients with diabetes 
and HF. These findings expand on previous research indicating an association between MDD 
and the number of comorbid conditions (Hayashino, Yamazaki, Takegami, Nakayama, & 
Sokejima, 2010).  
The sample resembled previous research samples as there were high rates of insomnia 
(51%), with past studies reporting insomnia in 33-64% of HF patients (Redeker, et al, 2010a; 
Brostrom & Johansson, 2005; Wang, et al, 2010). The significant rate of insomnia in patients 
with MDD has implications for treatment. While insomnia and hypersomnia are symptoms of 
MDD (APA, 2000), insomnia may be a risk factor for developing MDD, and treating insomnia 
or MDD without treating the other will lead to a relapse of both disorders (Sateia, 2009).  
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The most significant sleep symptom was feeling unrested during the day, with 80.6% of 
depressed patients reporting daytime fatigue.  All three symptoms of insomnia, difficulty 
initiating and maintaining sleep, and waking too early in the morning, were significantly 
associated with MDD. Fatigue and sleeping difficulties, along with poor appetite, have 
previously been described as the depressive symptoms most predictive of cardiovascular events 
(Hoen, et al., 2010). A thorough evaluation of sleep symptoms and insomnia may help providers 
identify patients most likely to have MDD. 
The six classes of medications most related to MDD were antidepressants, anxiolytics, 
insulin, sedative hypnotics, and a self report of taking sleeping pills (other than sedative 
hypnotics). The use of antidepressants and anxiolytics may be related to the high prevalence of 
MDD among patients with a past psychiatric history. Anxiety and MDD are related disorders and 
are often found together in clinical practice. First line treatment for both disorders is an SSRI. 
Though for many patients, use of an antidepressant alone may not alleviate symptoms of 
depression. The high rates of MDD among patients already on an antidepressant may indicate 
that these are patients requiring titration of their psychiatric medications, or perhaps patients with 
refractory depression who would benefit from medication management in a psychiatric setting. 
The high rate of MDD among patients with diabetes may explain the association between insulin 
and MDD. The use of sleep aids indicates difficultly sleeping, which is highly correlated with 
MDD in this population. 
Initially in our analysis we looked at the number of diagnoses (CCI) but found no 
significant between group differences for MDD and no MDD. We then conducted a multivariate 
analysis to look at the combined effect of the various individual characteristics with significant 
between group differences. Since many patients with stable HF have multiple diagnoses, the 
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combined regression allowed us to see how those factors affect each other. The multivariate 
analysis indicates that patients with insomnia have five-fold odds of having MDD; however, age, 
diabetes, and gender are also significantly associated with MDD. Surprisingly, unlike previous 
studies, we did not find that NYHA class was associated with MDD in these multivariate 
analyses. Whether these factors are causative of MDD or a result of MDD patients remains 
poorly understood. Additional research is needed to further explore their interaction.  
Limitations of the study include not screening for anxiety, as the initial study was 
investigating sleep, not depression. Additionally, we obtained limited information on psychiatric 
symptoms, history, and treatment. Diagnosis of MDD was not obtained by interview evaluating 
DSM-IV criteria; rather we selected a measure we thought would closely approximate clinical 
diagnosis. We also did not assess for functionality related to MDD. As this is a secondary 
analysis, information regarding anxiety symptoms, titration status of medications, and past 
medication trials, was not obtained. The cross sectional design has limitations in predicting and 
accounting for changes over time.  
Clinical Implications 
Despite recommendations to screen all HF patients for depression, time and other factors often 
do not allow for that screening to occur on a regular basis. Identifying readily available clinical 
factors that increase the odds of having MDD may help address this concern. Clinicians may 
benefit from knowing younger female patients with insomnia are most at risk for having MDD 
and can then conduct more focused screenings. The finding that insomnia symptoms were 
present in a large majority (83.9%) of depressed patients suggests that querying patients about 
insomnia symptoms may be a non-intrusive way of identifying patients with depression. HF 
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patients may feel more comfortable reporting sleep symptoms than depressive symptoms, and 
those reports may be indicative of depression. Patients reporting sleep symptoms should be 
evaluated for depression. One third of patients with MDD were on antidepressants, indicating 
that while initiating an antidepressant is a first step, medications must be titrated until clinical 
efficacy is obtained. Evaluation of depression should occur frequently to determine efficacy of 
treatment and need for additional dosages increases or switching to another agent. 
Research Implications 
 Further research is needed on treatment options for MDD and insomnia in this population. 
Additional research is needed to explore the associations between inflammatory medical 
conditions and MDD in HF patients, particularly implications for management. Future research 
may also evaluate the difference in effect of MDD and depressive symptoms on HF, and at what 
point treatment is indicated. 
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